127 related articles for article (PubMed ID: 15491777)
1. Is JAK3 a new drug target for immunomodulation-based therapies?
Papageorgiou AC; Wikman LE
Trends Pharmacol Sci; 2004 Nov; 25(11):558-62. PubMed ID: 15491777
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation.
Säemann MD; Zeyda M; Stulnig TM; Böhmig GA; Wekerle T; Hörl WH; Zlabinger GJ
Transpl Int; 2004 Oct; 17(9):481-9. PubMed ID: 15368094
[TBL] [Abstract][Full Text] [Related]
3. JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants.
Borie DC; O'Shea JJ; Changelian PS
Trends Mol Med; 2004 Nov; 10(11):532-41. PubMed ID: 15519279
[TBL] [Abstract][Full Text] [Related]
4. Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases.
Cetkovic-Cvrlje M; Uckun FM
Arch Immunol Ther Exp (Warsz); 2004; 52(2):69-82. PubMed ID: 15179321
[TBL] [Abstract][Full Text] [Related]
5. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
Pesu M; Candotti F; Husa M; Hofmann SR; Notarangelo LD; O'Shea JJ
Immunol Rev; 2005 Feb; 203():127-42. PubMed ID: 15661026
[TBL] [Abstract][Full Text] [Related]
6. JAK3 inhibition as a new concept for immune suppression.
Borie DC; Si MS; Morris RE; Reitz BA; Changelian PS
Curr Opin Investig Drugs; 2003 Nov; 4(11):1297-303. PubMed ID: 14758768
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling of the Jak3 kinase domains and structural basis for severe combined immunodeficiency.
Vihinen M; Villa A; Mella P; Schumacher RF; Savoldi G; O'Shea JJ; Candotti F; Notarangelo LD
Clin Immunol; 2000 Aug; 96(2):108-18. PubMed ID: 10900158
[TBL] [Abstract][Full Text] [Related]
8. JAK3 inhibitors in organ transplantation and autoimmune disease.
Xiong Z; Ma A; Chen H
Recent Pat Inflamm Allergy Drug Discov; 2010 Jan; 4(1):75-81. PubMed ID: 19832695
[TBL] [Abstract][Full Text] [Related]
9. Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors.
Vassilev AO; Tibbles HE; DuMez D; Venkatachalam TK; Uckun FM
Curr Drug Targets; 2006 Mar; 7(3):327-43. PubMed ID: 16515530
[TBL] [Abstract][Full Text] [Related]
10. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals.
Chen M; Cheng A; Chen YQ; Hymel A; Hanson EP; Kimmel L; Minami Y; Taniguchi T; Changelian PS; O'Shea JJ
Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6910-5. PubMed ID: 9192665
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.
Boggon TJ; Li Y; Manley PW; Eck MJ
Blood; 2005 Aug; 106(3):996-1002. PubMed ID: 15831699
[TBL] [Abstract][Full Text] [Related]
13. Jak3 and the pathogenesis of severe combined immunodeficiency.
O'Shea JJ; Husa M; Li D; Hofmann SR; Watford W; Roberts JL; Buckley RH; Changelian P; Candotti F
Mol Immunol; 2004 Jul; 41(6-7):727-37. PubMed ID: 15220007
[TBL] [Abstract][Full Text] [Related]
14. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154.
Säemann MD; Zeyda M; Diakos C; Szekeres A; Böhmig GA; Kelemen P; Parolini O; Stockinger H; Prieschl EE; Stulnig TM; Baumruker T; Zlabinger GJ
Transplantation; 2003 Jun; 75(11):1864-72. PubMed ID: 12811247
[TBL] [Abstract][Full Text] [Related]
15. Recent patents in the discovery of small molecule inhibitors of JAK3.
Wilson LJ
Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of Janus kinase 3 (JAK3) inhibitors.
Cetkovic-Cvrlje M; Tibbles HE
Curr Pharm Des; 2004; 10(15):1767-84. PubMed ID: 15180539
[TBL] [Abstract][Full Text] [Related]
17. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and evaluation of 4,6-diaminonicotinamide derivatives as novel and potent immunomodulators targeting JAK3.
Nakajima Y; Aoyama N; Takahashi F; Sasaki H; Hatanaka K; Moritomo A; Inami M; Ito M; Nakamura K; Nakamori F; Inoue T; Shirakami S
Bioorg Med Chem; 2016 Oct; 24(19):4711-4722. PubMed ID: 27544589
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase 3: a novel target for selective transplant immunosupression.
Podder H; Kahan BD
Expert Opin Ther Targets; 2004 Dec; 8(6):613-29. PubMed ID: 15584866
[TBL] [Abstract][Full Text] [Related]
20. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.
Cacalano NA; Migone TS; Bazan F; Hanson EP; Chen M; Candotti F; O'Shea JJ; Johnston JA
EMBO J; 1999 Mar; 18(6):1549-58. PubMed ID: 10075926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
